Standout Papers

Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplat... 2010 2026 2015 2020 651
  1. Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin (2010)
    Sarah D. Brown, Paola Nativo et al. Journal of the American Chemical Society
  2. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer (2023)
    Stephen J. Freedland, Murilo Luz et al. New England Journal of Medicine

Immediate Impact

2 from Science/Nature 63 standout
Sub-graph 1 of 22

Citing Papers

Prostate Cancer
2025 Standout
Renal cell carcinoma
2024 Standout

Works of Balaji Venugopal being referenced

Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).
2024
Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.
2022
and 1 more

Author Peers

Author Last Decade Papers Cites
Balaji Venugopal 337 255 85 433 323 52 1.3k
Guiyang Hao 283 302 49 495 185 48 1.6k
Chen Sun 155 147 47 431 280 52 1.4k
Xiaowei Ma 193 204 101 453 203 42 1.5k
Xiaohui Zheng 204 189 31 697 220 62 1.5k
Jun Shao 260 164 39 400 344 37 1.6k
Hong Zong 198 249 51 895 245 94 1.7k
Suresh Kumar Balasubramanian 182 119 55 296 188 48 1.2k
Hirokazu Miki 189 314 111 499 357 79 1.6k
Ming‐Feng Wei 171 123 39 542 337 39 1.3k
Bin Kong 118 147 68 569 215 46 1.5k

All Works

Loading papers...

Rankless by CCL
2026